294 related articles for article (PubMed ID: 30515151)
1. DAMP-Inducing Adjuvant and PAMP Adjuvants Parallelly Enhance Protective Type-2 and Type-1 Immune Responses to Influenza Split Vaccination.
Hayashi T; Momota M; Kuroda E; Kusakabe T; Kobari S; Makisaka K; Ohno Y; Suzuki Y; Nakagawa F; Lee MSJ; Coban C; Onodera R; Higashi T; Motoyama K; Ishii KJ; Arima H
Front Immunol; 2018; 9():2619. PubMed ID: 30515151
[TBL] [Abstract][Full Text] [Related]
2. Hydroxypropyl-β-cyclodextrin spikes local inflammation that induces Th2 cell and T follicular helper cell responses to the coadministered antigen.
Onishi M; Ozasa K; Kobiyama K; Ohata K; Kitano M; Taniguchi K; Homma T; Kobayashi M; Sato A; Katakai Y; Yasutomi Y; Wijaya E; Igarashi Y; Nakatsu N; Ise W; Inoue T; Yamada H; Vandenbon A; Standley DM; Kurosaki T; Coban C; Aoshi T; Kuroda E; Ishii KJ
J Immunol; 2015 Mar; 194(6):2673-82. PubMed ID: 25681338
[TBL] [Abstract][Full Text] [Related]
3. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
[TBL] [Abstract][Full Text] [Related]
4. IL-33 Is Essential for Adjuvant Effect of Hydroxypropyl-β-Cyclodexrin on the Protective Intranasal Influenza Vaccination.
Kobari S; Kusakabe T; Momota M; Shibahara T; Hayashi T; Ozasa K; Morita H; Matsumoto K; Saito H; Ito S; Kuroda E; Ishii KJ
Front Immunol; 2020; 11():360. PubMed ID: 32210964
[TBL] [Abstract][Full Text] [Related]
5. A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection.
Yamamoto T; Masuta Y; Momota M; Kanekiyo M; Kanuma T; Takahama S; Moriishi E; Yasutomi Y; Saito T; Graham BS; Takahashi Y; Ishii KJ
Int Immunol; 2019 Feb; 31(2):81-90. PubMed ID: 30535055
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
[TBL] [Abstract][Full Text] [Related]
7. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
[TBL] [Abstract][Full Text] [Related]
8. Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection.
Baldwin SL; Hsu FC; Van Hoeven N; Gage E; Granger B; Guderian JA; Larsen SE; Lorenzo EC; Haynes L; Reed SG; Coler RN
Front Immunol; 2018; 9():295. PubMed ID: 29515589
[TBL] [Abstract][Full Text] [Related]
9. Lipid Nanoparticles Potentiate CpG-Oligodeoxynucleotide-Based Vaccine for Influenza Virus.
Shirai S; Shibuya M; Kawai A; Tamiya S; Munakata L; Omata D; Suzuki R; Aoshi T; Yoshioka Y
Front Immunol; 2019; 10():3018. PubMed ID: 31998305
[TBL] [Abstract][Full Text] [Related]
10. The Carbomer-Lecithin Adjuvant Adjuplex Has Potent Immunoactivating Properties and Elicits Protective Adaptive Immunity against Influenza Virus Challenge in Mice.
Wegmann F; Moghaddam AE; Schiffner T; Gartlan KH; Powell TJ; Russell RA; Baart M; Carrow EW; Sattentau QJ
Clin Vaccine Immunol; 2015 Sep; 22(9):1004-12. PubMed ID: 26135973
[TBL] [Abstract][Full Text] [Related]
11. Novel Lipidated Imidazoquinoline TLR7/8 Adjuvants Elicit Influenza-Specific Th1 Immune Responses and Protect Against Heterologous H3N2 Influenza Challenge in Mice.
Miller SM; Cybulski V; Whitacre M; Bess LS; Livesay MT; Walsh L; Burkhart D; Bazin HG; Evans JT
Front Immunol; 2020; 11():406. PubMed ID: 32210973
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a quadrivalent seasonal influenza vaccine adjuvanted with hydroxypropyl-β-cyclodextrin: A phase 1 clinical trial.
Watanabe A; Nishida S; Burcu T; Shibahara T; Kusakabe T; Kuroda E; Ishii KJ; Kumanogoh A
Vaccine; 2022 Jul; 40(31):4150-4159. PubMed ID: 35672178
[TBL] [Abstract][Full Text] [Related]
13. Intranasal hydroxypropyl-β-cyclodextrin-adjuvanted influenza vaccine protects against sub-heterologous virus infection.
Kusakabe T; Ozasa K; Kobari S; Momota M; Kishishita N; Kobiyama K; Kuroda E; Ishii KJ
Vaccine; 2016 Jun; 34(27):3191-3198. PubMed ID: 27160037
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice.
Bhatnagar N; Kim KH; Subbiah J; Park BR; Ko EJ; Seong BL; Kang SM
Antiviral Res; 2022 Jan; 197():105229. PubMed ID: 34933043
[TBL] [Abstract][Full Text] [Related]
15. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.
van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF
Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus.
Fang Y; Rowe T; Leon AJ; Banner D; Danesh A; Xu L; Ran L; Bosinger SE; Guan Y; Chen H; Cameron CC; Cameron MJ; Kelvin DJ
J Virol; 2010 Sep; 84(17):8369-88. PubMed ID: 20534862
[TBL] [Abstract][Full Text] [Related]
17. Murine Cross-Reactive Nonneutralizing Polyclonal IgG1 Antibodies Induced by Influenza Vaccine Inhibit the Cross-Protective Effect of IgG2 against Heterologous Virus in Mice.
Shibuya M; Aoshi T; Kuroda E; Yoshioka Y
J Virol; 2020 Jun; 94(12):. PubMed ID: 32269125
[TBL] [Abstract][Full Text] [Related]
18. Overcoming the Neonatal Limitations of Inducing Germinal Centers through Liposome-Based Adjuvants Including C-Type Lectin Agonists Trehalose Dibehenate or Curdlan.
Vono M; Eberhardt CS; Mohr E; Auderset F; Christensen D; Schmolke M; Coler R; Meinke A; Andersen P; Lambert PH; Mastelic-Gavillet B; Siegrist CA
Front Immunol; 2018; 9():381. PubMed ID: 29541075
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
[TBL] [Abstract][Full Text] [Related]
20. The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine.
Wu F; Yuan XY; Li J; Chen YH
Vaccine; 2009 Jul; 27(32):4320-4. PubMed ID: 19410621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
